Literature DB >> 6301362

Pharmacokinetics of ceftriaxone in pediatric patients with meningitis.

R W Steele, L B Eyre, R W Bradsher, R E Weinfeld, I H Patel, J Spicehandler.   

Abstract

Pharmacokinetics of ceftriaxone after a single dose of 50 or 75 mg/kg were determined in 30 pediatric patients with bacterial meningitis. Data for doses of 50 and 75 mg/kg, respectively, were as follows (mean +/- standard deviation): maximum plasma concentrations, 230 +/- 64 and 295 +/- 76 mug/ml; elimination rate constant, 0.14 +/- 0.06 and 0.14 +/- 0.04 h(-1); harmonic elimination half-life, 5.8 +/- 2.8 and 5.4 +/- 2.1 h; plasma clearance, 51 +/- 24 and 55 +/- 18 ml/h per kg; volume of distribution, 382 +/- 129 and 387 +/- 56 ml/kg; mean concentration in cerebrospinal fluid 1 to 6 h after infusion, 5.4 and 6.4 mug/ml. A dosage schedule of 50 mg/kg every 12 h for bacterial meningitis caused by susceptible organisms is suggested for pediatric patients over 7 days of age.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6301362      PMCID: PMC186020          DOI: 10.1128/AAC.23.2.191

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

2.  Treatment of purulent meningitis with a new cephalosporin-Rocephin (Ro 13-9904). Clinical, bacteriological and pharmacological observations in 24 cases.

Authors:  M Cadoz; F Denis; H Félix; I Diop Mar
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

3.  Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin.

Authors:  M Seddon; R Wise; A P Gillett; R Livingston
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

4.  In vitro susceptibility of gram-negative bacilli from pediatric patients to moxalactam, cefotaxime, Ro 13-9904, and other cephalosporins.

Authors:  S Shelton; J D Nelson; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

5.  Ceftriaxone (Ro 13-9904) therapy of serious infection.

Authors:  R W Bradsher
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

6.  Ceftriaxone: in vitro studies and clinical evaluation.

Authors:  J W Gnann; W E Goetter; A M Elliott; C G Cobbs
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

7.  Single-dose pharmacokinetics of ceftriaxone in infants and young children.

Authors:  U B Schaad; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

8.  Pharmacokinetics of ceftriaxone in humans.

Authors:  I H Patel; S Chen; M Parsonnet; M R Hackman; M A Brooks; J Konikoff; S A Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

9.  In vivo activity of ceftriaxone (Ro 13-9904), a new broad-spectrum semisynthetic cephalosporin.

Authors:  G Beskid; J G Christenson; R Cleeland; W DeLorenzo; P W Trown
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

10.  Pharmacokinetics and bacteriologic efficacy of moxalactam, cefotaxime, cefoperazone, and rocephin in experimental bacterial meningitis.

Authors:  U B Schaad; G H McCracken; C A Loock; M L Thomas
Journal:  J Infect Dis       Date:  1981-02       Impact factor: 5.226

  10 in total
  33 in total

1.  In vitro antibiotic sensitivity pattern of common bacterial isolates from cases of acute bacterial meningitis with special reference to ceftriaxone.

Authors:  B N Rao; I M Kashbur; N M Shembesh; S M el Bargathy
Journal:  Indian J Pediatr       Date:  1997 Nov-Dec       Impact factor: 1.967

Review 2.  Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid.

Authors:  I Lutsar; I R Friedland
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

3.  Efficacy of single-dose ceftriaxone in experimental otitis media induced by penicillin- and cephalosporin-resistant Streptococcus pneumoniae.

Authors:  B Barry; M Muffat-Joly; J Bauchet; F Faurisson; P Gehanno; J J Pocidalo; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

Review 4.  Cephalosporins in adult meningitis.

Authors:  T R Beam
Journal:  Bull N Y Acad Med       Date:  1984-05

Review 5.  A perspective on new beta-lactam antibiotics in pediatric patients.

Authors:  J D Nelson
Journal:  Bull N Y Acad Med       Date:  1984-05

6.  The potential uses of ceftriaxone.

Authors:  W M Scheld
Journal:  Eur J Clin Microbiol       Date:  1983-10       Impact factor: 3.267

Review 7.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

8.  Comparison of ceftriaxone and traditional therapy of bacterial meningitis.

Authors:  B L Congeni
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

Review 9.  Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.

Authors:  Amanda K Sullins; Susan M Abdel-Rahman
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

10.  Increased resistance to multiple antimicrobials and altered resistance gene expression in CMY-2-positive Salmonella enterica following a simulated patient treatment with ceftriaxone.

Authors:  Russell D Hamilton; Holly J Hulsebus; Samina Akbar; Jeffrey T Gray
Journal:  Appl Environ Microbiol       Date:  2012-09-07       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.